Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.60 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.48 |
| ▸ | EBP | Q15125 | 2/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14431859 | 0.92 | CCR3 (0.54) | KCNA3CHRM4CHRM3KCNH2SIGMAR1 | |
| SCHEMBL5240018 | 0.90 | RAB9A (0.52) | KCNA3CHRM4CHRM3SIGMAR1EBP | |
| SCHEMBL14431920 | 0.89 | RAB9A (0.58) | KCNA3CHRM4CHRM3SIGMAR1EBP | |
| SCHEMBL14431854 | 0.89 | SIGMAR1 (0.51) | KCNA3CHRM4CHRM3KCNH2SIGMAR1 | |
| SCHEMBL5750440 | 0.86 | CCR3 (0.52) | KCNA3CHRM4CHRM3SIGMAR1EBP | |
| SCHEMBL5754473 | 0.86 | SIGMAR1 (0.49) | KCNA3CHRM4CHRM3KCNH2SIGMAR1 | |
| SCHEMBL5239794 | 0.85 | SIGMAR1 (0.60) | KCNA3SIGMAR1EBPCCR3 | |
| SCHEMBL5237846 | 0.85 | SIGMAR1 (0.60) | KCNA3CHRM4CHRM3SIGMAR1EBP | |
| SCHEMBL5235995 | 0.85 | CHRM4 (0.54) | KCNA3CHRM4CHRM3SIGMAR1EBP | |
| SCHEMBL5240261 | 0.84 | KCNH2 (0.53) | KCNH2SIGMAR1DRD2HTR1ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1818326-A1 | Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds | Eisai R&D Management Co., Ltd. (JP) | 2007-08-15 | — | — | EP | disclosed |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-04-20 | — | — | US | disclosed |
| US-6906072-B1 | Piperazine compound and pharmaceutical composition containing the compound | EISAI CO., LTD. (JP) | 2005-06-14 | — | — | US | disclosed |
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI CO., LTD. | 2004-11-04 | — | — | US | disclosed |
| EP-1254895-A1 | NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1D, CACNA1B, CACNA1E | KCNA3 278/4885CHRM4 457/4885CHRM3 343/4885 |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1B, CACNA1E, CACNA1D | KCNA3 225/4885CHRM4 256/4885CHRM3 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.